Finance

Lists
Why is XERS up 2,85%?
Dive Deeper
XERS:NASDAQ
Xeris Biopharma Holdings Inc
USD 10,48
+2,85%
(+0,29) 1D
USD 10,48
0,00% (0,00)
After hours
Closed: 9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XERS...
Open
USD 10,15
High
USD 10,60
Low
USD 10,07
Mkt. cap
1,91 mjd
Avg. vol.
2,79 m
Volume
3,00 m
52-wk high
USD 11,33
52-wk low
USD 5,25
EPS
-USD 0,11
Beta
0,68
Shares outstanding
182,32 m
No. of employees
435
Open
USD 10,15
High
USD 10,60
Low
USD 10,07
Mkt. cap
1,91 mjd
Avg. vol.
2,79 m
Volume
3,00 m
52-wk high
USD 11,33
52-wk low
USD 5,25
EPS
-USD 0,11
Beta
0,68
Shares outstanding
182,32 m
No. of employees
435
News stories
From web sources and news partners
About Xeris Biopharma Holdings Inc
CEO-
Employees435
Founded2005
HeadquartersChicago, Illinois, Verenigde State van Amerika
SectorPharmaceutical industry
Websitexerispharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to XERS in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for XERS in the last 3 months.
Highest
Current USD 10,48
USD 18,00 (+71,76%)
Average
USD 13,00 (+24,05%)
Lowest
USD 8,00 (-23,66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jenna Davidner
Barclays
Buy
Maintained
USD 14,00
+33,6%
10/06/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
USD 12,00
+14,5%
09/29/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
USD 10,00
-4,6%
09/21/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
USD 18,00
+71,8%
09/10/2026
David Amsellem
Piper Sandler
Hold
Reiterated
USD 8,00
-23,7%
09/10/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
USD 16,00
+52,7%
09/10/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
-USD 0,00 / USD 0,00
-172,00%miss
Revenue / Est. (USD)
92,10 m / 90,12 m
+2,19%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
74,38 m
85,81 m
83,13 m
92,10 m
Cost of goods sold
11,00 m
10,95 m
10,57 m
12,51 m
Cost of revenue
11,00 m
10,95 m
10,57 m
12,51 m
Research and development expenses
7,48 m
7,87 m
8,78 m
10,67 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46,46 m
47,50 m
53,14 m
61,04 m
Operating expense
56,65 m
58,09 m
64,64 m
74,42 m
Total operating expenses
67,65 m
69,03 m
75,21 m
86,93 m
Operating income
6,73 m
16,77 m
7,92 m
5,17 m
Other non operating income
-
-
-
-
EBT including unusual items
621,00 k
11,08 m
2,23 m
-31,10 m
EBT excluding unusual items
621,00 k
11,08 m
2,23 m
-319,00 k
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
621,00 k
11,08 m
2,23 m
-31,10 m
Net profit margin
0,83%
12,91%
2,69%
-33,77%
Earnings per share
-
0,06
0,01
-0,00
Interest and investment income
1,16 m
1,46 m
1,20 m
1,46 m
Interest expense
-7,27 m
-7,15 m
-6,88 m
-6,95 m
Net interest expenses
-6,11 m
-5,69 m
-5,68 m
-5,49 m
Depreciation and amortization charges
-
-
-
-
EBITDA
9,78 m
19,82 m
10,96 m
8,21 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme